Krystal Biotech, Inc. specializes in the discovery, development, and commercialization of redosable genetic medicines for rare and severe diseases. The company's core technology is based on an engineered, non-replicating herpes simplex virus type 1 (HSV-1) vector, which allows for repeated administration of gene therapies. Its flagship commercial product, VYJUVEK, is a topical gel approved for the treatment of dystrophic epidermolysis bullosa (DEB), a rare condition that causes extremely fragile skin. Beyond dermatology, Krystal's clinical pipeline spans multiple therapeutic areas, including respiratory conditions like cystic fibrosis and oncology programs targeting advanced solid tumors. The company is fully integrated, maintaining in-house capabilities for viral vector design, optimization, and commercial-scale gene therapy manufacturing.
